Over the past decades, it has been shown that each tumor has unique properties and structures (so-called neoepitopes) on its surface, distinguishing it from other tumors and healthy tissues. Hence, to improve the effectiveness of current cancer therapies, more personalized treatment approaches are required, individually directed against the novel neoepitope targets on the tumor.

To address this medical need, cecava’s therapy concept is to first analyze the tumor to identify the highly patient-individual neoepitopes using proprietary artificial intelligence-based algorithms. The identified neoepitopes are synthesized and formulated into vaccines that are thereby personalized for each patient. The vaccination of the patient induces a robust immune response against the neoepitopes of the tumor. Thereby, the power of the immune system is unleashed to effectively recognize and fight this tumor.

The first results from such treatments demonstrate the safety and potential of cecava’s approach for treating various cancer types. Based on these experiences, cecava is currently planning clinical trials.